The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
The start of a pivotal trial of Glaxosmithkline’s RSV vaccine adds another late-stage project to the pipeline for this underserved disease category.
Encouraging cholangitis data follows the lifting of a clinical hold on Cymabay’s seladelpar, signalling a way forward for a project that looked finished.
Newly-listed NGM Biopharmaceuticals needs its Nash project to impress in phase II, while Enanta must show that it also has a foot in the door in the liver disease.
A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…
A stumble for Inventiva’s lanifibranor in a rare fibrotic disease could bode ill for its prospects in Nash, and for those of other PPAR agonists.